Perceiv AI announced that the company has been selected by Merck for the inaugural Merck Digital Sciences Studio cohort, along with eight other early-stage biomedical startups from a pool of 152 applicants. The program started in November to fuel innovative digital technologies for drug discovery and development. MDSS is a collaboration between Merck and the New Jersey Innovation Institute, with investments from the Merck Global Health Innovation Fund, Northpond Ventures, and McKesson Ventures. The accelerator provides direct investment from Merck, access to powerful Azure Cloud computing, and technology support provided by Microsoft for Startups. Additionally, participating companies are provided opportunities to collaborate with discovery and clinical scientists at Merck for pilots, where appropriate.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports
- Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover
- Merck completes tender offer to acquire Imago BioSciences
- Merck, Pfizer rebuff China’s efforts to cut Covid drug prices, Bloomberg says
- Largest borrow rate increases among liquid names
